A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
New research analyzes the impact of hazardous waste management on US economic growth
Improper management of hazardous waste can contaminate soil and drinking water, release toxic air pollutants, and create serious health risks for exposed...